Amino acids, acylcarnitines and succinylacetone were extracted from a single 3.2 mm-diameter punch from each dried blood spot (DBS) using the
NeoBase Non-derivatized kit and, from 2019, the NeoBase 2 Non-derivatized kit (PerkinElmer, Turku, Finland) and quantified by flow injection analysis with ultra-performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS). These first-tier analyses were performed on two Acquity Xevo-TQS systems, an Acquity Xevo TQS micro or a
Quattro Premier XE (Waters, Milford, MA, USA). The first-tier cut-off values used for the 20 IEMs are depicted in
Table 1. In the case of an abnormal screening result in the first assessment, two new 3.2 mm diameter DBS punches were re-analyzed.
Biotinidase activity in DBSs was initially analyzed with a
Victor Multilabel Plate Reader (PerkinElmer, Turku, Finland) and measured by a semi-quantitative method using biotin-6-amidoquinoline as a substrate [4 (
link)]. From 2013, screening for biotinidase deficiency (BD) was performed using the Genetic Screening Processor (GSP
®) and the GSP Neonatal Biotinidase kit, both from PerkinElmer.
Tangeraas T., Sæves I., Klingenberg C., Jørgensen J., Kristensen E., Gunnarsdottir G., Hansen E.V., Strand J., Lundman E., Ferdinandusse S., Salvador C.L., Woldseth B., Bliksrud Y.T., Sagredo C., Olsen Ø.E., Berge M.C., Trømborg A.K., Ziegler A., Zhang J.H., Sørgjerd L.K., Ytre-Arne M., Hogner S., Løvoll S.M., Kløvstad Olavsen M.R., Navarrete D., Gaup H.J., Lilje R., Zetterström R.H., Stray-Pedersen A., Rootwelt T., Rinaldo P., Rowe A.D, & Pettersen R.D. (2020). Performance of Expanded Newborn Screening in Norway Supported by Post-Analytical Bioinformatics Tools and Rapid Second-Tier DNA Analyses. International Journal of Neonatal Screening, 6(3), 51.